New immunotherapy cocktails show promise for Tough-to-Treat stomach and esophageal cancers

NCT ID NCT03281369

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants were grouped by prior treatment history and received either a combination of immunotherapies or chemotherapy plus immunotherapy. The goal was to see if these combinations could shrink tumors and improve survival while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA OR ESOPHAGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM

    London, 0, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • Blacktown Hospital

    Blacktown, New South Wales, 2148, Australia

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Hospital Universitari Vall dHebron

    Barcelona, 08035, Spain

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • Mayo Clinic Cancer Center

    Scottsdale, Arizona, 85259, United States

  • Monash Medical Centre-Moorabbin Campus

    Clayton, Victoria, 3168, Australia

  • National Cheng Kung University Hospital

    Tainan, 70457, Taiwan

  • National Taiwan University Hospital (NTUH) - Cancer Research Center

    Zhongzheng Dist., 10051, Taiwan

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Rambam Health Care Campus

    Haifa, 3109601, Israel

  • Samsung Medical Center

    Seoul, 135-710, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital (SNUH) - Medical Oncology Center

    Seoul, 03080, South Korea

  • Sourasky Medical Centre

    Tel Aviv, 64239, Israel

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Tennessee Oncology - Nashville

    Nashville, Tennessee, 37203, United States

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, 442-723, South Korea

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden

    London, SW7 3RP, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton

    Sutton, SM2 5PT, United Kingdom

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030-4000, United States

  • UCLA Jonsson Comprehensive Cancer Center

    Santa Monica, California, 90404, United States

  • Uni of Southern California

    Los Angeles, California, 90033, United States

  • Universidad de Navarra - Clinica Universitaria de Navarra (CUN)

    Pamplona, Navarre, 31008, Spain

  • University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)

    Songpa-gu, 05505, South Korea

  • Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.